Kirk P Van Ness

USPTO Granted Patents = 8 (Patent Applications = 5)

CIPO Patents = 4

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 3.5

ph-index = 3

Forward Citations = 72(Granted Patents)

Location History:

Bainbridge Island, WA (US) (2010 - 2014)
Seattle, WA (US) (2005 - 2015)

Company Filing History:

Years Active: 2005-2015

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9045558 - Nucleic acids encoding modified human thymic stromal lymphopoietin (2015-06-02),

2. 8852591 - Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease (2014-10-07),

3. 8598318 - Modified human thymic stromal lymphopoietin (2013-12-03),

4. 7973151 - Nucleic acid encoding modified human thymic stromal lymphopoietin (2011-07-05),

5. 7709217 - Modified human thymic stromal lymphopoietin (2010-05-04),

6. 7452695 - Methods for increasing polypeptide production (2008-11-18),

7. 7288633 - Modified human thymic stromal lymphopoietin (2007-10-30),

8. 6872549 - Methods for increasing polypeptide production (2005-03-29),

Title: Kirk P Van Ness: Innovator in Immunology

Introduction

Kirk P Van Ness is a prominent inventor based in Seattle, WA, known for his significant contributions to the field of immunology. With a total of 8 patents to his name, he has made remarkable advancements in the understanding and treatment of autoimmune diseases.

Latest Patents

Among his latest patents, Van Ness has developed nucleic acids encoding modified human thymic stromal lymphopoietin. This includes modified, furin-resistant human TSLP polypeptides and polynucleotides encoding these modified polypeptides. His work also encompasses pharmaceutical compositions, B and T cell activation agents, assays, and methods of use. Another notable invention involves the combination of BLyS and/or APRIL inhibition with immunosuppressants for the treatment of autoimmune diseases. This innovative approach includes the use of Fc-fusion proteins, such as TACI-Fc, BAFF-R-Fc, and BCMA-Fc, to enhance treatment efficacy. The methods aim to reduce immunoglobulin levels in patients suffering from autoimmune conditions, utilizing various immunosuppressive drugs.

Career Highlights

Kirk P Van Ness has had a distinguished career, working with leading companies in the biotechnology sector. He has been associated with Immunex Corporation and Amgen Inc., where he contributed to groundbreaking research and development in immunology.

Collaborations

Throughout his career, Van Ness has collaborated with notable professionals in the field, including Stewart D Lyman and Raymond J Paxton. These collaborations have further enriched his research and innovations.

Conclusion

Kirk P Van Ness stands out as a key figure in the field of immunology, with a strong portfolio of patents that reflect his dedication to advancing medical science. His innovative approaches to treating autoimmune diseases continue to impact the healthcare landscape positively.

This text is generated by artificial intelligence and may not be accurate.